Spots Global Cancer Trial Database for accelerated phase

Every month we try and update this database with for accelerated phase cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey	NCT03647215	Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Ch...		18 Years -	Incyte Corporation
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)	NCT01077544	Chronic Myeloid... Acute Lymphobla...	Nilotinib	1 Year - 17 Years	Novartis
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia	NCT00171249	Philadelphia Po... Acute Lymphobla... Acute Myeloid L...	STI571 400 mg STI571 600 mg	18 Years -	Novartis
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia	NCT00171249	Philadelphia Po... Acute Lymphobla... Acute Myeloid L...	STI571 400 mg STI571 600 mg	18 Years -	Novartis
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase	NCT00449761	Leukemia, Myelo...	LBH589	18 Years -	Novartis
Asciminib Roll-over Study	NCT04877522	Chronic Myeloge... Leukemia, Myelo...	Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib	18 Years -	Novartis
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)	NCT01498445	Leukemia	Dasatinib Decitabine Decitabine	18 Years -	M.D. Anderson Cancer Center
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.	NCT01844765	Philadelphia Po...	nilotinib	1 Year - 17 Years	Novartis
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)	NCT00114959	Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi...	Homoharringtoni... Imatinib Mesyla...	16 Years -	Teva Branded Pharmaceutical Products R&D, Inc.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL	NCT04260022	Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso...	Ascentage Pharm... Blinatumomab	18 Years -	Ascentage Pharma Group Inc.
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)	NCT01077544	Chronic Myeloid... Acute Lymphobla...	Nilotinib	1 Year - 17 Years	Novartis
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase	NCT00449761	Leukemia, Myelo...	LBH589	18 Years -	Novartis
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.	NCT01605981	Chronic Myeloid...	AMN107	18 Years -	Novartis
An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha	NCT00171223	Leukemia, Myelo...	STI571	18 Years -	Novartis
Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.	NCT01605981	Chronic Myeloid...	AMN107	18 Years -	Novartis
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL	NCT04260022	Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso...	Ascentage Pharm... Blinatumomab	18 Years -	Ascentage Pharma Group Inc.
Asciminib Roll-over Study	NCT04877522	Chronic Myeloge... Leukemia, Myelo...	Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib	18 Years -	Novartis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: